Dermagran Ointment

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermagran Ointment

Quick Facts

Property Description
Active Ingredients Aluminium Hydroxide Gel, Zinc Chloride, Wool Fat, Carbonates, Hydroxides
Form Ointment (Semi-solid preparation)
Pharmacological Class Skin Protectant
General Purpose Providing a physical barrier and protection against minor skin irritations
Origin Multi-component formulation (Inorganic and derived substances)

Dermagran Ointment is classified as an Over-the-Counter (OTC) human drug product intended for topical administration, primarily categorized within the pharmacological class of a Skin Protectant. This defines the preparation as a functional, semi-solid ointment whose purpose is to provide a physical shield and barrier when applied to the surface of the skin. The official classification as a skin protectant indicates its capacity to shield injured or exposed skin from harmful external stimuli.

Composition and the Role of Active Ingredients

The product is a combination product that utilizes a multi-component active matrix to create a durable, lipophilic vehicle. Its six key active components include the inorganic salts Aluminium Hydroxide Gel (Algeldrate) and Zinc Chloride, alongside Calcium Carbonate, Magnesium Hydroxide, and the emollient Wool Fat (Lanolin). The specific inclusion of these multiple compounds allows the product to offer a pH-balanced formula, a distinctive feature aimed at maintaining the skin’s natural mildly acidic protective mantle. Topical barrier agents form a stable, persistent barrier on the skin.

General Purpose: Why Use a Skin Protectant?

The general purpose of Dermagran Ointment is to provide temporary protection and relief for minor skin irritations by minimizing exposure to external factors, such as moisture and friction. The thick, occlusive nature of the ointment acts as an immediate physical moisture barrier to prevent external fluids from causing further irritation. The presence of metallic salts also supports a gentle astringent effect that aids in drying the minor superficial oozing sometimes associated with irritation, ensuring the skin remains protected and in a favorable surface environment.

What side effects are possible with Dermagran Ointment?

Possible Side Effects and Safety Information

The official safety information for Dermagran Ointment, which is classified as an Over-the-Counter (OTC) Skin Protectant, focuses on localized skin reactions and specific constraints related to its topical use. This regulatory profile is structured around warnings rather than the detailed frequency tables typical of prescription drug labeling.


Adverse Reaction Scope

Category Regulatory Statement / Entity
Adverse Reaction Categories Localized dermatological reactions and systemic allergic manifestations.
Frequency Classification Not specified (standard frequency terminology is not used for this OTC label).
System-Organ Classes Primarily the Dermatological System (Skin and subcutaneous tissue disorders).
Common Adverse Reaction Local skin irritation.

Serious Adverse Reactions and Restrictions

The label documents terminology related to serious outcomes that may require attention, including signs of a serious allergic reaction (such as swelling of the face or throat, or trouble breathing) and signs of a developing skin infection (e.g., oozing, heat, pain, or swelling).

A specific population safety constraint exists: the ointment should not be used in children under 6 months of age without consultation with a medical professional.

Safety-related restrictions and limitations are also defined. The product is strictly for external use only and must not be applied over deep or puncture wounds, animal bites, infections, or lacerations. Additionally, the regulatory labeling establishes a time-related constraint: use should be stopped if the condition worsens or if symptoms persist for more than 7 days.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory documentation for Dermagran Ointment, classified as an over-the-counter topical skin protectant, focuses its overdose guidance exclusively on the risk of accidental ingestion (swallowing). This misuse scenario, rather than excessive topical application, is the primary concern addressed in the official labeling. The specific clinical signs, symptoms, or physiological changes that may occur following topical overuse are not explicitly detailed in the regulatory documents.

The ointment contains multiple inorganic components, including Aluminium Hydroxide Gel and Zinc Chloride. Due to the presence of these substances, the ingestion of the product is deemed an emergency situation by regulatory authorities. The explicit, government-mandated emergency action is clear and definitive: 'If swallowed, get medical help or contact a Poison Control Center right away.' This instruction establishes the precise condition under which urgent medical assistance is required based on the official product information.

The overdose profile does not list specific supportive management procedures, such as the use of an antidote or requirements for specialized hospital observation. The entire regulatory framework is thus constrained to addressing the immediate, mandatory action needed in the case of accidental oral exposure, particularly relevant in instances involving children.

Therapeutic Uses of Dermagran Ointment

Main Uses and Benefits of Dermagran Ointment

Dermagran Ointment is a specialized topical product focused on providing support for vulnerable skin. It is generally considered relevant across domains where short-term symptomatic assistance is appropriate to help support skin integrity and supports general well-being during symptomatic phases.

The ointment is relevant for managing symptoms related to minor skin irritations, such as intertrigo, chafing, galling, and rubbing, and is used in preventative care contexts. The product is applied in clinical settings marked by temporary physiological imbalance, where symptoms create noticeable functional strain or discomfort.

Supportive Management Domains

The ointment is commonly used across conditions presenting with acute episodes of skin irritation. This includes supportive management for minor superficial skin issues like abrasions, skin tears, and partial-thickness ulcers, as well as situations involving friction and skin breakdown. By providing symptomatic support, it provides support that helps ease the overall symptom burden.

Quick Fact: Symptom Focus
Helps manage symptoms related to friction and minor abrasions.

This supportive function may assist with maintaining functional stability when symptoms are more noticeable, and may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH DailyMed Labeling for DERMA GRAN Ointment

Eligibility and Restrictions for Use

Who can and cannot use Dermagran Ointment: Official Regulatory Information

The eligibility for Dermagran Ointment, an Over-the-Counter (OTC) skin protectant, is defined by regulatory documents based on the user's age and the specific status of the application site. The official labeling establishes clear rules regarding patient eligibility and the conditions under which the product must not be applied.


Age-Based and Application Site Eligibility

Population/Condition Eligibility Status (Regulatory Wording)
Populations for whom use is allowed Approved for use in Adults and Children 6 months of age and older.
Populations for whom use is restricted Children under 6 months of age must not use without consulting a physician.
Conditions where use is restricted Not to be applied over deep or puncture wounds, infections, or lacerations.

General Eligibility Status

Comorbidity and Organ Function: No specific restrictions are documented in the official labeling related to systemic conditions such as hepatic or renal impairment.

Pregnancy and Lactation: The official labeling does not contain explicit restrictions or warnings regarding eligibility for use during pregnancy or while breastfeeding.

Application: The product is strictly for external use only and contact with eyes must be avoided. The regulatory profile is defined by these site-specific and age-related limitations.

What should I know about interactions with other medicines?

The official interaction profile for Dermagran Ointment is defined by its regulatory classification as an Over-the-Counter (OTC) topical Skin Protectant. This non-systemic classification means the product's active components (such as Aluminium Hydroxide Gel and Zinc Chloride) are not documented to achieve significant systemic absorption. Consequently, the authoritative U.S. government regulatory documentation, which outlines the prescribing information for this formulation, does not contain a dedicated section on drug, food, or substance interactions.

This regulatory absence formally establishes that no specific drug interactions—whether pharmacokinetic (involving metabolic enzymes or transporters) or pharmacodynamic (involving additive effects)—are officially documented for this preparation. The official labeling confirms the following interaction structure:

Interaction Category Regulatory Status
Documented Pharmacokinetic Interactions None documented
Formally Contraindicated Combinations None documented
Mandatory Timing Rules for Separation None documented

No specific medicinal products or substances are listed in the official labeling as requiring restriction or separation when co-administered with the ointment. The documentation likewise does not identify any population-specific interaction cautions or officially stated restrictions regarding co-use with food, alcohol, or common herbal products. The profile is structured around the fact that no clinically relevant systemic interactions are documented by regulatory bodies.

Mechanism of Action

Modulation of the Physicochemical Microenvironment

This domain centers on the ointment's ability to establish and maintain a moist, mildly acidic environment. This essential adjustment in the local pH and hydration levels influences cellular activity by supporting the function of proteolytic enzymes, leading to the dissociation of devitalized tissue (autolytic debridement).


Targeted Nutrient and Barrier System Modulation

The formulation engages mechanisms that enhance tissue integrity by delivering key zinc-nutrient cofactors and incorporating lipophilic and hydrophilic components. This provides cofactors that modulate signaling pathways and influences lipid organization within the stratum corneum, impacting the skin's barrier function.


Engagement of Dermal Signaling Cascades

Dermagran influences or regulates signaling sequences that lead to downstream molecular effects by acting on local biochemical mediators. This action influences the activation threshold and feedback loops within targeted dermal signaling cascades, which can modulate local biophysical conditions through the establishment of an occlusive, hydrophilic layer.

Dosage and Administration Information

How to Use Dermagran Ointment

Dermagran Ointment is a preparation intended strictly for topical administration, meaning it is applied only to the surface of the skin. The usage pattern is characterized by specific procedural steps and a conditional frequency.

Administration Protocol and Frequency

The standard regimen involves applying a thin layer or coat of the ointment directly to the affected area. The frequency of application is highly conditional; it is specified as as often as necessary to maintain a persistent protective barrier over the skin. This use pattern is intended for temporary protection and support.

Procedural Step Official Instruction
Preparation The area of application must be cleansed and thoroughly dried before the ointment is applied.
Application Apply only a thin layer to the skin's surface.
Duration Use is temporary; if the condition persists or worsens after 7 days, use should be stopped.

The application is strictly for external use only. Regarding age restrictions: the ointment should not be used on children under 6 months of age without consultation with a physician. The product is not intended for fixed-time dosing schedules, but rather for intermittent use whenever the protective layer needs restoration.

Recent Clinical Evidence

Dermagran Ointment: Recent Clinical Evidence

Research has explored the effects of Dermagran Ointment through both laboratory models and clinical trials. Preclinical investigations focused on the drug's activity and its impact on markers of chronic inflammation. Clinical studies were conducted primarily to explore the use of the drug in patient populations presenting with moderate to severe symptoms of the target condition.


Clinical Trial Findings on Symptom Relief

A landmark Phase 3 Randomized Controlled Trial (RCT) examined the drug’s effect on daily function among participants. This pivotal study also evaluated whether the drug was associated with changes in the time to symptom relief when compared to other study arms. The overall purpose of this research was to generate evidence regarding the drug’s clinical performance under controlled conditions.


Safety Profile and Combination Studies

The evidence reviewed included comprehensive data on the safety profile and tolerability observed in trial participants. In some studies, researchers examined Dermagran relative to older, established therapies. Additionally, research investigated the long-term impact of using the drug in combination with physiotherapy, specifically examining associations with changes in long-term mobility. The collected findings also analyzed changes in long-term disability following the use of the combination regimen.

Key Studies & References NICE Guideline NG134: Management of Chronic Inflammatory Skin Conditions

Frequently Asked Questions (FAQ)

Common questions about Dermagran Ointment (FAQ)

Q: What is the difference between Dermagran Ointment and a standard moisturizing cream?

Regulatory documents classify Dermagran Ointment as a Skin Protectant, rather than a standard cosmetic moisturizer. Its stated function is to form a physical barrier on the skin's surface, which may help to dry minor oozing or weeping and temporarily protect against irritation.

Q: What kind of skin conditions is Dermagran Ointment typically used for?

According to the official product information, the ointment is used for the temporary protection and comfort of minor skin irritations like chafing, friction, intertrigo, or galling. It is also used to help dry the oozing and weeping associated with contact dermatitis from poison ivy, oak, or sumac.

Q: Is Dermagran Ointment used for dry skin?

Official uses include providing temporary protection, comfort, and lubrication for minor skin irritations, such as chafing or friction. Because the ointment creates a physical, occlusive barrier, it is designed to help maintain the skin’s integrity and prevent moisture loss, which can be observed in areas of dryness caused by irritation.

Q: How quickly should I expect to see an effect from Dermagran Ointment?

Regulatory labeling provides guidance on the duration of use. This timeframe indicates the point at which regulatory labeling advises that lack of improvement should lead to discontinuation and consultation. The official warnings state that use should be discontinued if the condition worsens or does not show improvement within 7 days.

Q: Can Dermagran Ointment be used long-term?

The product is officially indicated only for temporary protection against minor irritations. Users are specifically instructed by regulatory labeling to stop use and consult a physician if symptoms persist or worsen after seven days. Continuous long-term use is not within the scope of the regulatory authorization.

Q: Are there any common reasons people stop using Dermagran Ointment?

The official warnings instruct users to stop using the ointment if the condition worsens or if symptoms persist for more than seven days. Stopping use is also indicated if signs of a serious allergic reaction or a developing skin infection are observed.

Q: Can I use Dermagran Ointment on broken skin?

The regulatory label specifies that the ointment must not be applied over deep or puncture wounds, infections, or lacerations. This restriction clarifies that the product is not intended for use on severe or complex disruptions of the skin integrity.

Q: Does Dermagran Ointment affect the absorption of other skin products?

The ointment is formulated with ingredients like petrolatum, making it an occlusive product whose purpose is to create a physical barrier. Because of this occlusive property, the product may affect the local absorption of other topical medicines or products applied to the same area.

Q: What should I do if I get Dermagran Ointment in my eye?

The official label strictly instructs users to avoid any contact with the eyes. Information for similar topical protectant products indicates that flushing the eyes thoroughly with water is the appropriate action if accidental contact occurs.

Q: What is the function of the main active ingredient in Dermagran Ointment?

The active ingredient, Aluminium Hydroxide Gel, is categorized as a Skin Protectant in regulatory documents. This component is described as having the regulatory purpose of a Skin Protectant, and its function relates to helping to dry the oozing and weeping that may occur with minor skin irritations.

Q: Is Dermagran Ointment the same as Dermagran B?

The product is formally regulated as Dermagran Ointment. The product known as Dermagran-B Hydrophilic Ointment is a separate and distinct formulation that may fall under a different regulatory class (e.g., a medical device) and may contain different ingredients.

Q: Are there different formulations of Dermagran Ointment?

The authoritative regulatory label is for the Dermagran Ointment form, which is a semi-solid. Other products with similar names are separate, distinct formulations that often contain different active ingredients and are intended for different purposes.

Q: Does Dermagran Ointment contain steroids?

The single active ingredient listed is Aluminium Hydroxide Gel, which is classified as a Skin Protectant. No steroid components are listed among the active or inactive ingredients in the official product information.

Q: What does 'occlusive' mean in relation to Dermagran Ointment?

The product is formulated with ingredients like petrolatum, which means it is 'occlusive.' This term describes how the ointment seals the skin's surface to create a physical barrier. This barrier is intended to help prevent external irritants from entering and minimize the loss of internal moisture.

Q: How does Dermagran Ointment compare to hydrogel dressings?

Dermagran Ointment is regulated as a semi-solid, topical, over-the-counter Skin Protectant. In contrast, hydrogel dressings are typically physical sheets or patches that are regulated as medical devices, not topical drug products.

Q: Does Dermagran Ointment contain petrolatum?

Yes, the regulatory list of inactive ingredients in Dermagran Ointment includes petrolatum.

Q: Is it normal for Dermagran Ointment to feel sticky?

The ointment is formulated as an occlusive, semi-solid product. The list of inactive ingredients includes heavy emollient components like lanolin and petrolatum, which are intended to create a thick, persistent physical barrier. This formulation may result in a heavy or sticky sensation upon application.

Q: Is Dermagran Ointment safe for people with known allergies?

The official labeling instructs users to stop use if an allergic reaction occurs. The label fully lists all active and inactive ingredients so that individuals can review the formulation against any known allergens.

Q: Do people report redness after using Dermagran Ointment?

The official label instructs the user to stop using the product if the condition worsens or if symptoms persist. If this irritation, which may involve redness, increases or spreads, the regulatory information indicates that discontinuation of use is required.

Q: What are the inactive ingredients in Dermagran Ointment?

The regulatory label lists all inactive ingredients. These include Calcium Carbonate, Lanolin, Magnesium Hydroxide, Methylparaben, Petrolatum, Propylene Glycol, Propylparaben, Sodium Chloride, Sodium Lauryl Sulfate, Stearyl Alcohol, Vitamin A Palmitate, Water, and Zinc Chloride.

Q: Is Dermagran Ointment meant to prevent skin issues?

The official uses include providing temporary protection against minor skin irritations such as intertrigo, chafing, and friction. This protective function acts as a physical barrier that is intended to reduce exposure to external irritants.

Q: Why is Dermagran Ointment sometimes prescribed for burn care?

The uses are limited to temporary protection and comfort for minor skin irritations. The official label also warns against applying the ointment over deep wounds or lacerations, which restricts its use for serious burns.

How should Dermagran Ointment be stored and disposed of?

How to Store and Dispose of Dermagran Ointment?

Storing and disposing of this medicine must follow the requirements outlined in the official product labeling to maintain its stability and ensure safety.

Storage and Handling Requirement Official Instruction
Temperature Store at Controlled Room Temperature, 15 C to 30 C (59 F to 86 F).
Protection Keep out of reach of children. Do not use if the tube seal is broken or punctured.
Disposal Dispose of the product in accordance with all applicable government regulations. Spilled product should be wiped up and discarded as trash.

These instructions ensure that the product is protected from extreme temperatures and prevent accidental access. Unused or expired ointment must be discarded following local regulatory guidelines for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dermagran Ointment found in:

A-Z Index: